Libra Health Receives Seed Funding to Create Supplements for Female Athletes
The Ventures has announced its investment in Libra Health, a brand focused on creating menstrual-cycle-tailored supplements specifically for female athletes. This seed funding, disclosed on August 20, aims to address the unique performance challenges that female athletes face due to hormonal fluctuations throughout their menstrual cycles. Research from University College London has highlighted that elite female athletes experience a significantly increased risk of muscle injuries during certain phases of their cycle, particularly the pre-menstrual and early-to-mid luteal phases. Despite this, many existing sports nutrition products for women have not adequately addressed these needs, often merely repackaging male-oriented formulas without considering the hormonal and metabolic changes women experience.
Libra Health's founder and CEO, Yullee Lee, has a personal connection to this issue, having faced her own health challenges, including two bouts with cancer. Her experiences led her to study inflammation and hormonal health extensively, ultimately inspiring the creation of Libra Health. The company is preparing to establish itself as a U.S. entity and has developed a regulatory-compliance framework tailored for the American women's sports market.
The debut product, named 'Golden,' refers to the Latin term corpus luteum, which is associated with the luteal phase of the menstrual cycle. This product aims to reframe the luteal phase as a 'Golden opportunity' for athletes. Importantly, 'Golden' is formulated without hormone-modulating ingredients to eliminate any risks related to doping regulations, and the company is pursuing certification through Informed-Sport or a similar program to ensure its safety for athletes. The formulation incorporates Korean fermentation techniques, utilizing kimchi-derived probiotics and plant-based ingredients to enhance gut health and manage inflammation, thereby addressing performance variability linked to the menstrual cycle.
Libra Health is currently in the process of identifying U.S.-based production facilities and research partners that meet the certification standards for athlete supplements. The global market for women's sports nutrition is projected to grow significantly, from an estimated $23.8 billion in 2026 to $55.4 billion by 2036. Instead of relying on large marketing budgets, Libra Health emphasizes athlete validation as a key strategy, collaborating directly with female athletes in U.S. collegiate and professional leagues to refine their products.
The funding from this seed round will support product development, certification processes, initial production runs, and athlete trial programs. Libra Health plans to initiate pilot distribution to U.S. college sports teams in the fourth quarter of 2026, with a full commercial launch anticipated in the first quarter of 2027.




